Mexidol 0.125 mg – 50 tablets


Mexidol is combined with all drugs used to treat somatic diseases. Enhances the effect of benzodiazepine drugs, antidepressants, anxiolytics, anticonvulsants and antiparkinsonian drugs. Reduces the toxic effects of ethyl alcohol.


Active ingredients: ethylmethylhydroxypyridine succinate
Country of origin Russia
Manufacturer ZiO-Health, JSC
Release form 50 tablets per pack
Keep out of reach of children
Dosage form
Coated tablets from white to white with a creamy shade, round, biconvex.
ethylmethylhydroxypyridine succinate 125 mg
Excipients: lactose monohydrate, povidone, magnesium stearate.
Sheath composition: opadry II white 33G28435 (hypromellose, titanium dioxide, lactose monohydrate, polyethylene glycol (macrogol), triacetin)
general description
Antioxidant drug
Special conditions
Influence on the ability to drive vehicles and control mechanisms
During the period of treatment, care must be taken when driving vehicles and engaging in other potentially hazardous activities that require increased concentration of attention and speed of psychomotor reactions.
Drug interactions
Mexidol® is combined with all drugs used to treat somatic diseases. Enhances the effect of benzodiazepine drugs, antidepressants, anxiolytics, anticonvulsants and antiparkinsonian drugs. Reduces the toxic effects of ethyl alcohol.
Mexidol® is an inhibitor of free radical processes, a membrane protector with antihypoxic, stress-protective, nootropic, anticonvulsant and anxiolytic effects. The drug increases the body’s resistance to the effects of various damaging factors (shock, hypoxia and ischemia, cerebral circulation disorders, alcohol and antipsychotic drugs (neuroleptics) intoxication).
The mechanism of action of Mexidol® is due to its antioxidant, antihypoxant and membrane-protective action. It inhibits lipid peroxidation, increases the activity of superoxide dismutase, increases the lipid-protein ratio, reduces the viscosity of the membrane, and increases its fluidity. Mexidol® modulates the activity of membrane-bound enzymes (calcium independent phosphodiesterase, adenylate cyclase, acetylcholinesterase), receptor complexes (benzodiazepine, GABA, acetylcholine), which enhances their ability to bind to ligands, contributes to the preservation of the structural and functional organization of biomembranes and transport of neuromembranes. Mexidol® increases the content of dopamine in the brain. It causes an increase in the compensatory activation of aerobic glycolysis and a decrease in the degree of inhibition of oxidative processes in the Krebs cycle under conditions of hypoxia with an increase in the content of ATP and creatine phosphate, activation of the energy-synthesizing functions of mitochondria, and stabilization of cell membranes.
The drug improves metabolism and blood supply to the brain, improves microcirculation and rheological properties of blood, reduces platelet aggregation. It stabilizes the membrane structures of blood cells (erythrocytes and platelets) during hemolysis. Has a hypolipidemic effect, reduces the content of total cholesterol and low density lipoproteins.
The antistress effect is manifested in the normalization of post-stress behavior, somato-vegetative disorders, restoration of sleep-wakefulness cycles, impaired learning and memory processes, reduction of dystrophic and morphological changes in various structures of the brain.
Mexidol® has a pronounced antitoxic effect in case of withdrawal symptoms. It eliminates the neurological and neurotoxic manifestations of acute alcohol intoxication, restores behavioral disorders, autonomic functions, and is also able to relieve cognitive impairment caused by long-term ethanol intake and its cancellation. Under the influence of Mexidol®, the effect of tranquilizing, neuroleptic, antidepressant, hypnotics and anticonvulsants is enhanced, which makes it possible to reduce their doses and reduce side effects. Mexidol® improves the functional state of the ischemic myocardium. In conditions of coronary insufficiency, it increases the collateral blood supply to the ischemic myocardium, contributes to the preservation of the integrity of cardiomyocytes and the maintenance of their functional activity. Effectively restores myocardial contractility in reversible cardiac dysfunction.
It is rapidly absorbed when taken orally. The maximum concentration at doses of 400 – 500 mg is 3.5 – 4.0 μg / ml. It is quickly distributed in organs and tissues. The average retention time of the drug in the body when ingested is 4.9 – 5.2 hours. It is metabolized in the liver by glucuron conjugation. 5 metabolites have been identified: 3-hydroxypyridine phosphate – formed in the liver and, with the participation of alkaline phosphatase, decomposes into phosphoric acid and 3-hydroxypyridine; 2nd metabolite – pharmacologically active, is formed in large quantities and is found in urine 1 – 2 days after administration; 3rd – excreted in large quantities in the urine; 4th and 5th – glucuron conjugates. T1 / 2 when taken orally – 2.0 – 2.6 hours. Rapidly excreted in the urine, mainly in the form of metabolites and insignificantly quality – unchanged. It is most intensively excreted during the first 4 hours after taking the drug. The indicators of excretion in the urine of unchanged drug and metabolites have individual variability.
– Consequences of acute disorders of cerebral circulation, including after transient ischemic attacks, in the phase of subcompensation as preventive courses;
– slight traumatic brain injury, the consequences of traumatic brain injury;
– encephalopathy of various origins (dyscirculatory, dysmetabolic, post-traumatic, mixed);
– syndrome of vegetative dystonia;
– mild cognitive disorders of atherosclerotic genesis;
– anxiety disorders in neurotic and neurosis-like states;
-ischemic heart disease as part of complex therapy;
– relief of withdrawal symptoms in alcoholism with a predominance of neurosis-like and vegetative-vascular disorders, post-withdrawal disorders;
– conditions after acute intoxication with antipsychotic drugs;
– asthenic conditions, as well as for the prevention of the development of somatic diseases under the influence of extreme factors and loads;
– exposure to extreme (stress) factors.
Acute hepatic and / or renal failure, increased individual sensitivity to the drug.
Due to insufficient knowledge of the effect of the drug – children’s age, pregnancy, breastfeeding
In case of an overdose, drowsiness may develop.
Side effects
From the digestive system: dyspepsia.
Others: allergic reactions.
You can buy MEXIDOL 0.125 N50 TABL P / PLEN / SHELL in Moscow at a pharmacy convenient for you by placing an order on
The price of MEXIDOL 0.125 N50 TABLES P / PLEN / SHELL in Moscow is 431 rubles.
Instructions for use for MEXIDOL 0.125 N50 TABL P / PLEN / SHELL.